SCHEMBL683604

SCHEMBL683604

COc1ccc(N2CCN(Cn3cnc4c3c(=O)n(C)c(=O)n4C)CC2)cc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 3/20 0.62
HTR7 P34969 1/20 0.59
HTR6 P50406 1/20 0.59
LMNA P02545 1/20 0.57
CYP2C9 P11712 1/20 0.56
HSD17B10 Q99714 1/20 0.56
RAB9A P51151 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.54
ALDH1A1 P00352 4/20 0.54
SMN1; SMN2 Q16637 3/20 0.54
MAPT P10636 3/20 0.54
MAPK1 P28482 1/20 0.54
TDP1 Q9NUW8 1/20 0.54
ALOX15 P16050 2/20 0.54
TSHR P16473 2/20 0.54
NPSR1 Q6W5P4 1/20 0.54
HTT P42858 1/20 0.53
KMT2A Q03164 1/20 0.53
TP53 P04637 1/20 0.53
KDM4E B2RXH2 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11148728 0.92 RXFP1 (0.65) RXFP1HTR7HTR6LMNACYP2C9
SCHEMBL684041 0.91 HTR7 (0.58) RXFP1HTR7HTR6LMNACYP2C9
SCHEMBL683994 0.89 RXFP1 (0.63) RXFP1HTR7HTR6LMNARAB9A
SCHEMBL682813 0.88 HTR7 (0.62) RXFP1HTR7HTR6LMNARAB9A
SCHEMBL682817 0.87 LMNA (0.62) RXFP1HTR7HTR6LMNARAB9A
SCHEMBL684362 0.87 RAB9A (0.71) RXFP1HTR7HTR6LMNAHSD17B10
SCHEMBL683655 0.87 HTR7 (0.77) RXFP1HTR7HTR6LMNAHSD17B10
SCHEMBL684028 0.84 HTR7 (0.58) RXFP1HTR7HTR6LMNARAB9A
SCHEMBL683998 0.83 HTR7 (0.57) RXFP1HTR7HTR6LMNARAB9A
SCHEMBL684027 0.82 SMN1; SMN2 (0.60) RXFP1HTR7HTR6LMNARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110269717-A1 NEUROGENESIS BY MODULATING ANGIOTENSIN BRAINCELLS INC. (US) 2011-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110269717-A1 NEUROGENESIS BY MODULATING ANGIOTENSIN NGF, DCX, BDNF RXFP1 211/4885HTR7 1398/4885HTR6 683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.